Evidence-based·Updated November 20, 2026·How we grade evidence

Modafinil

MedicationWakefulness drug (prescription, Schedule IV)

Modafinil (Provigil and generics) is a Schedule IV prescription tablet that reduces excessive daytime sleepiness in adults with narcolepsy, obstructive sleep apnea and shift work disorder. In randomized trials it kept people awake longer on objective tests and improved how sleepy they felt, though many still had some sleepiness. In healthy, rested adults its effect on thinking is small. Rare but serious skin and allergic reactions, psychiatric symptoms and reduced effectiveness of hormonal birth control are the key cautions.

Taking Modafinil with other supplements or medications?Check your whole list for interactions. Free, no account.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults with diagnosed narcolepsy, obstructive sleep apnea with ongoing sleepiness despite airway treatment, or shift work disorder, prescribed and monitored by a doctor

Common dosing range

Set by your prescriber. Label dose: 200 mg once a day in the morning for narcolepsy or OSA; 200 mg about 1 hour before the work shift for shift work disorder; half the dose in severe liver impairment; consider lower doses in older adults

When to expect effects

Blood levels peak 2 to 4 hours after a dose; trial benefits were measured over 4 to 12 weeks

Watch out for

No boxed warning. The label tells patients to stop it and contact their doctor right away at the first sign of rash, hives, mouth sores, blisters, swelling or trouble swallowing or breathing (serious rash including Stevens-Johnson syndrome, and multi-organ allergic reactions). It can cause anxiety, mania or psychosis, more patients on it needed new or higher blood pressure medicine, and hormonal birth control may fail during use and for one month after. Schedule IV controlled substance

What is it

Modafinil is an FDA-approved prescription medicine that promotes wakefulness, sold as Provigil and as generic 100 mg and 200 mg tablets. Its current label approves it for one purpose: to improve wakefulness in adults with excessive sleepiness from narcolepsy, obstructive sleep apnea (OSA) or shift work disorder. In OSA it treats the sleepiness, not the blocked airway, so CPAP or other airway treatment continues. In the US it is a Schedule IV controlled substance, it is not approved for children, and the European Medicines Agency removed its OSA indication in 2011. Modafinil is a mixture of two mirror-image forms; armodafinil is its R-form. People also use it off-prescription as a "smart drug" to boost focus, which is not an approved use.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have narcolepsy, obstructive sleep apnea with persistent sleepiness despite CPAP or other airway treatment, or diagnosed shift work disorder, and your doctor prescribes it
You and your prescriber have reviewed your other medicines, especially hormonal birth control, cyclosporine, warfarin and drugs cleared by CYP2C19
You understand it reduces sleepiness but may not bring wakefulness back to normal and is not a replacement for sleep

Probably skip if…

You want it as a "smart drug" to study or work longer: in healthy, rested adults the measured benefit on thinking is small, and it is not approved for this use
You have had an allergic reaction to modafinil or armodafinil (contraindicated), or a serious rash with either
You have left ventricular hypertrophy, or mitral valve prolapse syndrome triggered by stimulants before: the label says it is not recommended
You would buy it without a prescription: it is a Schedule IV controlled substance dispensed only on prescription

Evidence at a glance

excessive daytime sleepiness in narcolepsy

Good Evidence
Effect
Significant improvement in objective and self-rated sleepiness over 9 weeks; similar to sodium oxybate and pitolisant
Best fit
Adults with narcolepsy whose main problem is daytime sleepiness
Time
Measured over 9 weeks

residual sleepiness in obstructive sleep apnea despite CPAP

Good Evidence
Effect
Epworth score about 2.2 points better and wakefulness test about 3 minutes longer than placebo
Best fit
Adults with OSA who use CPAP or other airway treatment and remain sleepy
Time
Measured at about 4 weeks

excessive sleepiness in shift work disorder

Good Evidence
Effect
Clinical improvement in 74% versus 36% on placebo
Best fit
People with diagnosed chronic shift work disorder
Time
Measured monthly over 3 months

thinking skills in healthy, rested adults ("smart drug" use, off-label)

Limited Evidence
Effect
Overall SMD 0.12 on cognitive tests (small)
Best fit
None established
Time
Hours after a single dose in lab studies

Evidence for 4 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

excessive daytime sleepiness in narcolepsy

Disease adjunct
Good Evidence

Two US 9-week double-blind trials randomized people with narcolepsy to modafinil 200 mg, 400 mg or placebo daily (283 people at 18 centers, and 271 people at 21 centers). Modafinil significantly improved objective sleepiness on the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test, self-rated sleepiness on the Epworth Sleepiness Scale, and clinician-rated illness; nighttime sleep was not harmed. When treatment was stopped in the second trial, sleepiness returned to baseline without amphetamine-like withdrawal. A network meta-analysis of 14 randomized trials found modafinil 200 to 400 mg had efficacy on sleepiness similar to sodium oxybate 9 g and pitolisant up to 40 mg, but only the latter two showed a benefit on cataplexy. A 2022 network meta-analysis of 19 trials (2,504 patients) found solriamfetol better than modafinil on the wakefulness test (SMD 0.42, 95% CI 0.05 to 0.79). The placebo-controlled trials lasted 9 weeks.

Effect size
Significant improvement in objective and self-rated sleepiness over 9 weeks; similar to sodium oxybate and pitolisant
Time to effect
Measured over 9 weeks
Best fit
Adults with narcolepsy whose main problem is daytime sleepiness
Less likely
People seeking control of cataplexy, which modafinil did not show

Bottom line: Modafinil reliably reduces daytime sleepiness in narcolepsy, with effects that fade when it is stopped.

residual sleepiness in obstructive sleep apnea despite CPAP

Disease adjunct
Good Evidence

A meta-analysis of 10 randomized placebo-controlled trials (1,466 adults with OSA still sleepy despite CPAP) found modafinil or armodafinil improved the Epworth Sleepiness Scale by 2.2 points (95% CI 1.5 to 2.9) and the Maintenance of Wakefulness Test by 3 minutes (95% CI 2.1 to 3.8). They tripled adverse events and doubled withdrawals because of adverse events, but did not increase serious adverse events. A 2023 network meta-analysis of 14 trials (3,085 patients) rated the 4-week improvement on the wakefulness test as high certainty (SMD 0.41) and on the Epworth scale as moderate certainty (mean difference -2.25); modafinil-armodafinil probably doubled discontinuation for adverse events (risk ratio 2.01), and solriamfetol was likely more effective. The European Medicines Agency removed the OSA indication in 2011, citing an unfavorable benefit-risk balance. Long-term effects were not well studied.

Effect size
Epworth score about 2.2 points better and wakefulness test about 3 minutes longer than placebo
Time to effect
Measured at about 4 weeks
Best fit
Adults with OSA who use CPAP or other airway treatment and remain sleepy
Less likely
People not treating the airway itself, which modafinil does not fix

Bottom line: Modafinil modestly reduces leftover sleepiness in treated sleep apnea, at the cost of more side effects.

excessive sleepiness in shift work disorder

Disease adjunct
Good Evidence

In a 3-month double-blind trial, 209 people with chronic shift work sleep disorder took 200 mg modafinil or placebo before each night shift. Nighttime sleep latency improved modestly (1.7 versus 0.3 minutes; P = 0.002), more people improved clinically (74% versus 36%; P < 0.001), lapses of attention fell (a reduction of 2.6 versus an increase of 3.8; P < 0.001), and fewer reported accidents or near accidents driving home (29% versus 54%; P < 0.001). Daytime sleep was not harmed. Despite these gains, people on modafinil still had excessive sleepiness and impaired performance at night. This was a single trial.

Effect size
Clinical improvement in 74% versus 36% on placebo
Time to effect
Measured monthly over 3 months
Best fit
People with diagnosed chronic shift work disorder
Less likely
Shift workers who are tired but do not meet criteria for the disorder

Bottom line: Modafinil helps night-shift workers with shift work disorder stay more alert, but it does not make them fully alert.

thinking skills in healthy, rested adults ("smart drug" use, off-label)

Supplement benefit
Limited Evidence

This is not an approved use. A 2020 meta-analysis of 14 studies (64 effect sizes) in healthy adults who were not sleep-deprived found a small overall effect of modafinil on cognitive tests (SMD 0.12, p = .01), mainly on memory updating (SMD 0.28). The authors concluded that the effects are small, in experiments that do not reflect real-world use, and that the common perception that these drugs are effective cognitive enhancers is not supported by the evidence. A 2015 systematic review found that most simple tests showed better executive function, only half showed better attention or memory, and a few showed worse divergent creative thinking, while more complex tasks showed more consistent gains. The studies were mostly single doses in laboratories; long-term effects in healthy people were not studied.

Effect size
Overall SMD 0.12 on cognitive tests (small)
Time to effect
Hours after a single dose in lab studies
Best fit
None established
Less likely
Healthy, well-rested people expecting a large boost in focus or grades

Bottom line: In healthy, rested adults, modafinil's effect on thinking is small and the "smart drug" reputation outruns the evidence.

How it works

The label says the way modafinil promotes wakefulness is unknown. It binds the dopamine transporter in the brain and blocks dopamine reuptake, raising dopamine levels in some brain regions in animals, but it is not a direct dopamine agonist. Its wake-promoting effects resemble those of amphetamine and methylphenidate, though its profile is not identical, and in people it can produce euphoric and other stimulant-like effects. After a tablet, blood levels peak in 2 to 4 hours; food does not change how much is absorbed but can delay the peak by about an hour. The effective half-life after repeated doses is about 15 hours, and steady levels are reached in 2 to 4 days. The liver clears about 90% of it. Modafinil speeds up the liver enzyme CYP3A4, which can lower levels of hormonal birth control and some other drugs, and it slows the enzyme CYP2C19, which can raise levels of drugs such as omeprazole, phenytoin and diazepam.

How to take it

1. Typical dose
Your prescriber sets the dose. Label: for narcolepsy or obstructive sleep apnea, 200 mg by mouth once a day as a single morning dose; for shift work disorder, 200 mg once a day about 1 hour before the start of the work shift. In severe liver impairment the label halves the dose, and it advises considering lower doses with close monitoring in older adults.
2. Higher studied dose
Doses up to 400 mg a day as a single dose were well tolerated in trials, but the label says there is no consistent evidence that 400 mg gives more benefit than 200 mg.
3. Timing
Morning for narcolepsy and OSA; about an hour before the shift for shift work disorder, as the label states.
4. With food
With or without food: the label says food does not change overall absorption but can delay the peak level by about an hour.
5. Split dosing
The label doses are single daily doses.
6. How long to try
Long-term as your prescriber decides. In a narcolepsy trial, sleepiness returned to baseline levels when people stopped, without amphetamine-like withdrawal symptoms. The label says it may be critical to keep using earlier treatments such as CPAP.

What to track

Any rash, hives, mouth sores, blisters, peeling skin, swelling of the face, lips or throat, or trouble swallowing or breathing; the label says to stop and contact your doctor right away. Most serious rashes began 1 to 5 weeks after starting
Fever with rash and signs of other organ problems (such as yellowing skin), which can mean a multi-organ allergic reaction
Chest pain, a racing or irregular heartbeat, and blood pressure and heart rate if your doctor asks you to check them
New anxiety, depression, mania, unusual thoughts or hallucinations
How sleepy you still are, especially before driving or other risky activities
If you use hormonal birth control, a backup or different method during treatment and for one month after, as the label advises

Bottom line: One tablet a day at the time the label sets for your condition; your prescriber sets the dose and checks your other medicines, especially birth control.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Headache: 34% on modafinil versus 23% on placebo in pooled trialsNausea (11% versus 3%), nervousness (7% versus 3%), anxiety (5% versus 1%) and trouble sleeping (5% versus 1%)Runny nose (7% versus 6%), back pain (6% versus 5%), diarrhea (6% versus 5%), dizziness (5% versus 4%) and indigestion (5% versus 4%)Loss of appetite, dry mouth, chest pain, high blood pressure, palpitations and fast heartbeat, each in 2% to 4%8% of patients stopped because of side effects, versus 3% on placebo; headache and anxiety rose with dose

Serious risks

  • No boxed warning. Serious rash, including Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS: in trials in children, rash leading to discontinuation occurred in about 0.8% (13 of 1,585), including a possible case of Stevens-Johnson syndrome; rare serious or life-threatening rashes have been reported in adults and children. Nearly all serious cases began 1 to 5 weeks after starting. The label says to stop modafinil at the first sign of rash unless it is clearly not drug-related.

  • Angioedema, anaphylaxis and multi-organ allergic reactions: swelling of the face, lips, tongue or throat has been reported after approval, and multi-organ hypersensitivity reactions, including at least one death, have occurred a median of 13 days after starting, often with fever and rash plus heart, liver or blood involvement.

  • Psychiatric symptoms: mania, delusions, hallucinations, suicidal thoughts and aggression have been reported after approval, some leading to hospitalization; many but not all patients had a prior psychiatric history. The label advises caution with a history of psychosis, depression or mania.

  • Heart effects: chest pain, palpitations and ECG changes occurred in trial participants with mitral valve prolapse or left ventricular hypertrophy, and one man had a 9-second pause in heartbeat. More patients on modafinil needed new or higher blood pressure medicine (2.4% versus 0.7% on placebo). The label says it is not recommended with left ventricular hypertrophy or stimulant-related mitral valve prolapse syndrome, and to consider more monitoring after a recent heart attack or unstable angina.

  • Abuse and misuse: modafinil is a Schedule IV controlled substance. In people experienced with drugs of abuse it produced euphoric and psychoactive effects consistent with other scheduled stimulants such as methylphenidate, and the label says patients, especially those with a history of stimulant abuse, should be watched for misuse. Fatal overdoses involving modafinil alone or with other drugs have been reported, and accidental swallowing has occurred in children as young as 11 months.

  • Persistent sleepiness and driving: wakefulness may not return to normal, and patients may not notice their sleepiness until asked. The label says it is not a replacement for sleep and that patients should not change driving or other risky activities until it is clear their wakefulness permits them.

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: the label (Pregnancy Category C) says there are no adequate and well-controlled studies in pregnant women. Restricted fetal growth and miscarriage have been reported with modafinil and armodafinil, but whether they were caused by the drug is unknown; in rats and rabbits, harm to the developing fetus occurred at exposures similar to human doses. The label says to use it in pregnancy only if the benefit justifies the risk, and a pregnancy registry exists (1-866-404-4106). Hormonal birth control, including pills, shots and implants, may not work during treatment and for one month after stopping, so the label recommends another or an additional method. Breastfeeding: it is not known whether modafinil passes into human milk, and the label advises caution. Talk with your doctor about pregnancy plans and feeding your baby.

Interactions

Hormonal birth control (steroidal contraceptives such as ethinyl estradiol pills, and depot or implant forms)High

Modafinil speeds up the liver enzyme CYP3A4, which clears these hormones, so the label says their effectiveness may be reduced during treatment and for one month after stopping. In a study, ethinyl estradiol exposure fell 18%. The label recommends an alternative or additional method of contraception during that time; talk to your prescriber.

Cyclosporine and other CYP3A4 medicines (such as midazolam and triazolam)Moderate

By speeding up CYP3A4, modafinil can lower blood levels of these drugs: in one transplant patient, cyclosporine levels fell 50% after a month, and triazolam exposure fell 59% in a study. The label says to monitor cyclosporine levels and consider dose adjustments; your prescriber decides any change.

Medicines cleared by CYP2C19 (such as omeprazole, phenytoin, diazepam, propranolol and clomipramine)Moderate

Modafinil slows the enzyme CYP2C19, so these drugs can build up: armodafinil raised omeprazole exposure by 40%. In people who lack the CYP2D6 enzyme, levels of some antidepressants (tricyclics and SSRIs) may also rise. The label says dose adjustments may be needed; ask your pharmacist to review your list.

WarfarinModerate

Modafinil may affect CYP2C9, the enzyme that clears S-warfarin. A single-dose study found no significant change, but an interaction cannot be ruled out, so the label advises more frequent INR checks when the two are used together.

MAO inhibitors (monoamine oxidase inhibitors)Moderate

The label says caution should be used when MAO inhibitors and modafinil are given together. Tell your prescriber if you take any MAO inhibitor.

AlcoholLow

The Provigil and Nuvigil labels say the use of modafinil or armodafinil in combination with alcohol has not been studied, and advise that it is prudent to avoid alcohol while taking them; the Medication Guide says it is not known how drinking alcohol will affect you on the medicine. This is label advice for an untested combination, not an observed interaction. Tell your prescriber how much you usually drink.

Documented interactions

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

Prescription tablets of modafinil 100 mg or 200 mg (the 200 mg tablet is scored), as brand Provigil or generic modafinil, dispensed by a pharmacy with a prescription in your name
Labeled as containing modafinil, a Schedule IV controlled substance
Dispensed with an FDA-approved Medication Guide, which the label says patients should read
Brand Provigil tablets are debossed "PROVIGIL" on one side and the strength on the other

Be skeptical of…

"Limitless pill" or "proven smart drug": in healthy, rested adults the measured effect on thinking is small (SMD 0.12), and this use is not approved
"Replaces sleep": the label says it is not a replacement for sleep and wakefulness may not return to normal
"No prescription needed" or "legal to buy online": it is a Schedule IV controlled substance that requires a prescription
"Not addictive" or "no side effects": the label describes euphoric effects and abuse potential, serious rash, allergic and psychiatric reactions
"Safe with the pill": the label says hormonal birth control may fail during treatment and for one month after
"Treats sleep apnea": it treats sleepiness in OSA, not the blocked airway, and CPAP or other airway treatment should continue

Frequently asked questions

Is modafinil approved as a smart drug or for focus?⌄

No. Its only approved use is to improve wakefulness in adults with excessive sleepiness from narcolepsy, obstructive sleep apnea or shift work disorder. In healthy, rested adults, a meta-analysis of 14 studies found only a small effect on cognitive tests, and the authors said the popular view of it as an effective cognitive enhancer is not supported by the evidence.

Is it legal to buy modafinil online without a prescription?⌄

In the US, modafinil is a Schedule IV controlled substance, so it is dispensed only with a prescription.

Does modafinil affect birth control?⌄

Yes. The label says hormonal contraceptives, including pills, shots and implants, may be less effective while taking modafinil and for one month after stopping, and it recommends an alternative or additional method during that time. Talk with your prescriber about which method to use.

Can I take modafinil with my supplements, coffee or alcohol?⌄

There are no studies of modafinil with supplements; the one food or drink interaction listed on this page is alcohol, based on label advice. The label says the combination with alcohol has not been studied and that it is prudent to avoid alcohol. In a study with armodafinil, the label reports no significant effect on the enzyme that clears caffeine. Because modafinil changes the liver enzymes CYP3A4 and CYP2C19, ask your doctor or pharmacist to check your full list, including supplements.

Is modafinil addictive?⌄

It has some abuse potential: it is a Schedule IV controlled substance, and in people experienced with drugs of abuse it produced euphoric effects similar to methylphenidate. In one 9-week trial, no withdrawal symptoms were seen over 14 days after stopping, although sleepiness returned in people with narcolepsy. The label says patients with a history of stimulant abuse should be followed closely.

How does it compare with stimulants like amphetamine?⌄

The label says modafinil's wake-promoting effects are similar to amphetamine and methylphenidate, but its pharmacology is not identical. It is not a direct dopamine agonist, though it blocks dopamine reuptake.

References by claim

excessive daytime sleepiness in narcolepsy

PMID 9450772 · PubMed (1998) link

PMID 10720292 · PubMed (2000) link

Lehert et al., 2018 · PMC (2018) link

Chien et al., 2022 · PMC (2022) link

residual sleepiness in obstructive sleep apnea despite CPAP

Chapman et al., 2016 · PubMed (2016) link

Pitre et al., 2023 · PubMed (2023) link

excessive sleepiness in shift work disorder

Czeisler et al., 2005 · PubMed (2005) link

thinking skills in healthy, rested adults ("smart drug" use, off-label)

Roberts et al., 2020 · PubMed (2020) link

Battleday et al., 2015 · PubMed (2015) link

Safety

Provigil (modafinil) prescribing information · DailyMed (FDA label) link

Interaction: Alcohol

Nuvigil (armodafinil) prescribing information · DailyMed (FDA label) link

Track Modafinil with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 20, 2026·Evidence current as of Nov 20, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.